Valuation: GlaxoSmithKline Pharmaceuticals Limited

Market Cap 488B 5.11B 4.41B 4.15B 3.77B 7.1B 7.21B 48.65B 19.04B 245B 19.17B 18.75B 815B P/E 2027 *
42.1x
P/E 2028 * 36.6x
Enterprise Value 488B 5.11B 4.41B 4.15B 3.77B 7.1B 7.21B 48.65B 19.04B 245B 19.17B 18.75B 815B EV / Sales 2027 *
11.5x
EV / Sales 2028 * 10.4x
Free-Float
-
Yield 2027 *
1.02%
Yield 2028 * 1.02%

Last Transcript: GlaxoSmithKline Pharmaceuticals Limited

1 day+6.46%
1 week+10.63%
Current month+8.36%
1 month+17.22%
3 months+17.98%
6 months+10.52%
Current year+16.32%
1 week 2,579.5
Extreme 2579.5
2,919
1 month 2,445.4
Extreme 2445.4
2,919
Current year 2,088.1
Extreme 2088.1
2,919
1 year 2,088.1
Extreme 2088.1
2,919
3 years 1,385.05
Extreme 1385.05
3,515.7
5 years 1,227
Extreme 1227
3,515.7
10 years 962.65
Extreme 962.65
3,515.7
Manager TitleAgeSince
Chief Executive Officer 56 2022-11-30
Director of Finance/CFO - 2026-03-31
Chief Tech/Sci/R&D Officer - 2024-07-07
Director TitleAgeSince
Chairman 73 2019-03-31
Director/Board Member 59 2020-05-17
Director/Board Member 67 2022-05-15
Change 5-day change 1-year change 3-year change Capi.($)
+6.46%+10.63% - - 4.78B
+3.60%-0.50%+74.80%+127.97% 1,055B
+3.33%+3.55%+53.48%+55.80% 632B
+3.43%+4.42%+25.27%+72.59% 442B
+1.35%-3.27%+40.98%+39.91% 351B
+1.75%-0.98%+26.20%+39.73% 290B
+2.13%-1.53%+1.85%+9.40% 243B
+1.41%+1.94%+43.45%+61.18% 227B
+1.35%-3.20%-9.07%-53.51% 200B
+3.25%+7.80%+21.18%+87.50% 172B
Average +2.11%-1.44%+30.90%+48.95% 401.39B
Weighted average by Cap. +1.31%-1.87%+43.73%+68.76%

Financials

2027 *2028 *
Net sales 42.53B 445M 384M 361M 328M 618M 627M 4.24B 1.66B 21.3B 1.67B 1.63B 70.96B 47.17B 493M 426M 400M 364M 686M 696M 4.7B 1.84B 23.62B 1.85B 1.81B 78.7B
Net income 11.61B 121M 105M 98.57M 89.68M 169M 171M 1.16B 453M 5.82B 456M 446M 19.37B 13.36B 140M 121M 113M 103M 194M 197M 1.33B 521M 6.69B 524M 513M 22.3B
Net Debt - -
Logo GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company has three product areas: vaccines, specialty and general medicine. Its general medicines business has a portfolio of medicines in anti-infectives, pain, vitamins medicine, nutritional, hormones, dermatologicals, respiratory and vaccines for adults and children. The Company's general medicine brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, Tenovate, T-bact and Physiogel. The Company's vaccine brands include Shingrix Herpes Zoster Vaccine, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicine brands include Nucala, Seretide, and Trelegy Ellipta. Trelegy Ellipta, single inhaler triple therapy (SITT) for chronic obstructive pulmonary disease (COPD) patients. The Subsidiary of the Company is Biddle Sawyer Limited.
Employees
3,103
Date Price Change Volume
26-08-18 ₹2,877.40 +6.46% 477,841
26-08-17 ₹2,702.90 +0.52% 84,337
26-08-14 ₹2,688.80 +0.79% 94,952
26-08-13 ₹2,667.70 +1.81% 59,367
26-08-12 ₹2,620.20 +0.70% 64,718
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2,883.20INR
Average target price
3,081.00INR
Spread / Average Target
+6.86%

Quarterly revenue - Rate of surprise